Anna Berkenblit
Director/Board Member at SURROZEN, INC.
Net worth: 3 M $ as of 2024-01-30
Profile
Anna Berkenblit is currently the Director at Surrozen Operating, Inc., the Independent Director at Surrozen, Inc., and the Director at Nested Therapeutics, Inc. Previously, she held positions as the Chief Medical Officer & Senior Vice President at ImmunoGen, Inc., Vice President at Pfizer Inc., Vice President & Head-Clinical Research at AVEO Pharmaceuticals, Inc., and Senior Vice President-Clinical Development at H3 Biomedicine, Inc. She has a graduate degree from Harvard University and the Massachusetts Institute of Technology, an undergraduate degree from Yale University, and a doctorate from Harvard Medical School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
IMMUNOGEN, INC.
0.04% | 2023-12-28 | 101,612 ( 0.04% ) | 3 M $ | 2024-01-30 |
Anna Berkenblit active positions
Companies | Position | Start |
---|---|---|
SURROZEN, INC. | Director/Board Member | 2018-07-31 |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Director/Board Member | 2019-03-13 |
Nested Therapeutics, Inc.
Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nested Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company focuses on discovering and developing novel, targeted, small molecule precision medicine therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and have a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI. Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations to reach a broader group of patients. The company was founded by Arvin Dar and Klaus Hoeflich. The CEO is Darrin Miles. | Director/Board Member | - |
Former positions of Anna Berkenblit
Companies | Position | End |
---|---|---|
IMMUNOGEN, INC. | Chief Tech/Sci/R&D Officer | 2023-08-30 |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | 2014-12-31 |
AVEO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2012-12-31 |
PFIZER, INC. | Corporate Officer/Principal | 2011-08-31 |
Training of Anna Berkenblit
Harvard University | Graduate Degree |
Massachusetts Institute of Technology | Graduate Degree |
Yale University | Undergraduate Degree |
Harvard Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
PFIZER, INC. | Health Technology |
SURROZEN, INC. | Health Technology |
Private companies | 5 |
---|---|
AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Nested Therapeutics, Inc.
Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nested Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company focuses on discovering and developing novel, targeted, small molecule precision medicine therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and have a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI. Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations to reach a broader group of patients. The company was founded by Arvin Dar and Klaus Hoeflich. The CEO is Darrin Miles. | Commercial Services |
- Stock Market
- Insiders
- Anna Berkenblit